Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.

G Gatti1, A Bartoli, R Marchiselli

  • 1Clinical Pharmacology Unit, Department of Internal Medicine, University of Pavia, Italy.

British Journal of Clinical Pharmacology
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accuracy and reliability of an augmented reality prototype for robot-assisted partial nephrectomy: a preclinical study with 3D-printed kidney phantoms (UroCCR 168).

Journal of robotic surgery·2026
Same author

Intracranial complications of sinogenic and otogenic infections in children: an ESPN survey on their occurrence in the pre-COVID and post-COVID era.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2024
Same author

The impact of a history of status epilepticus for epilepsy surgery outcome.

Epilepsy research·2024
Same author

Probing artificial intelligence in neurosurgical training: ChatGPT takes a neurosurgical residents written exam.

Brain & spine·2024
Same author

Endovascular therapies for hepatic artery stenosis post liver transplantation.

CVIR endovascular·2022
Same author

Automatic preoperative 3d model registration in laparoscopic liver resection.

International journal of computer assisted radiology and surgery·2022
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Vigabatrin (VGB) does not reduce oral absorption of phenytoin (PHT). While VGB slightly lowers serum PHT levels, this interaction is not due to decreased bioavailability, suggesting other mechanisms are involved.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Epilepsy Treatment

Background:

  • Phenytoin (PHT) is a common antiepileptic drug.
  • Vigabatrin (VGB) is another antiepileptic medication.
  • Potential drug interactions between VGB and PHT require investigation.

Purpose of the Study:

  • To investigate if vigabatrin (VGB) decreases serum phenytoin (PHT) concentration by affecting PHT's oral bioavailability.
  • To explore the mechanism behind observed decreases in serum PHT levels during combined VGB and PHT therapy.

Main Methods:

  • Study included 21 epilepsy patients on PHT therapy.
  • Patients were switched between oral and intravenous PHT administration before and after a course of VGB.
  • Serum PHT concentrations and urinary metabolite excretion were monitored.

Related Experiment Videos

Main Results:

  • Serum PHT concentrations showed a slight but statistically significant decrease after VGB treatment (P < 0.05).
  • A subgroup of patients exhibited a more pronounced decrease in serum PHT levels (P < 0.005).
  • Switching to intravenous PHT confirmed that oral bioavailability of PHT remained unaffected by VGB.

Conclusions:

  • Vigabatrin (VGB) does not alter the oral bioavailability of phenytoin (PHT).
  • The observed reduction in serum PHT concentrations during VGB treatment is mediated by mechanisms other than altered oral absorption.
  • Further research is needed to elucidate the exact mechanisms of this drug interaction.